Australia fines Roche for marketing violations

Roche was fined $400,000 for violations of Medicines Australia's code of conduct, including an offer to fund a nurse's salary if a clinic increased use of Pegasys, its hepatitis C drug. Report

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.